Back to Search Start Over

Molecular features of glioblastomas in long-term survivors compared to short-term survivors-a matched-pair analysis.

Authors :
Sommerlath, Vivien N.
Buergy, Daniel
Etminan, Nima
Brehmer, Stefanie
Reuss, David
Sarria, Gustavo R.
Guiot, Marie-Christin
Hänggi, Daniel
Wenz, Frederik
Petrecca, Kevin
Giordano, Frank A.
Source :
Radiation Oncology; 1/24/2022, Vol. 17 Issue 1, p1-8, 8p
Publication Year :
2022

Abstract

<bold>Background: </bold>Although glioblastoma (GB) is associated with a devastating prognosis, a small proportion of patients achieve long-term survival rates. We herein present a matched-pair analysis of molecular factors found in long- and short-term survivors (LTS, STS).<bold>Methods: </bold>We performed a cross-institutional analysis of 262 patient records and matched a group of 91 LTS (≥ 3 years) with two groups of STS (STS-1, n = 91; STS-2, n = 80). Matching was performed according to age, Karnofsky Performance Status, initial therapy and adjuvant therapy. Molecular factors were compared between LTS (total of 91 patients) v. STS-1, and LTS (subgroup of 80 patients) v. STS-2. We included glial fibrillary acidic protein (GFAP), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, isocitrate dehydrogenase 1 (IDH-1); furthermore, the proliferation index was analyzed (Ki-67/MIB-1).<bold>Results: </bold>IDH-1 and decreased Ki-67 were numerically associated with LTS but the difference was only significant compared to STS-1 (n.s. v. STS-2). LTS was associated with MGMT promoter hypermethylation (p = 0.013 and p = 0.022) and GFAP expression (p < 0.001 and p = 0.001). Positivity for both factors combined compared to negativity for one factor occurred more often in the LTS group (p = 0.002 and p = 0.006); negativity for both factors combined did not occur in the LTS group.<bold>Conclusion: </bold>In this retrospective analysis, GFAP expression and MGMT promoter methylation were associated with LTS. Given the hypothesis-generating nature of our study, these observations should be confirmed in prospective clinical trials. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
1748717X
Volume :
17
Issue :
1
Database :
Complementary Index
Journal :
Radiation Oncology
Publication Type :
Academic Journal
Accession number :
154871020
Full Text :
https://doi.org/10.1186/s13014-022-01984-w